Get the Stockscreener App
1.995
4.45%
0.085
Tuhura Biosciences Inc stock is traded at $1.995, with a volume of 73,555.
It is up +4.45% in the last 24 hours and down -18.57% over the past month.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
See More
Previous Close:
$1.91
Open:
$1.91
24h Volume:
73,555
Relative Volume:
0.38
Market Cap:
$102.26M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.55%
1M Performance:
-18.57%
6M Performance:
-29.26%
1Y Performance:
-68.23%
1-Day Range:
$1.90
$2.00
1-Week Range:
$1.80
$2.14
52-Week Range:
$1.56
$6.90
Tuhura Biosciences Inc Stock (HURA) Company Profile
Name
Tuhura Biosciences Inc
Sector
Industry
Phone
813-875-6600
Address
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
1.995 | 97.90M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-25 | Initiated | H.C. Wainwright | Buy |
| Dec-19-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-05-24 | Initiated | Maxim Group | Buy |
Tuhura Biosciences Inc Stock (HURA) Latest News
What drives TuHURA Biosciences Inc stock pricePortfolio Diversification Tips & Superior Capital Growth - earlytimes.in
Will TuHURA Biosciences Inc. (PL3) stock deliver compounding returnsMarket Performance Summary & Fast Moving Stock Watchlists - Newser
Will TuHURA Biosciences Inc. stock reach all time highs in 2025July 2025 Opening Moves & Intraday High Probability Alerts - Newser
Is TuHURA Biosciences Inc. (PL3) stock a buy during volatile markets2025 Analyst Calls & Consistent Profit Trade Alerts - Newser
Can TuHURA Biosciences Inc. (PL3) stock deliver double digit returnsWeekly Market Report & Safe Entry Point Alerts - Newser
Can TuHURA Biosciences Inc. (PL3) stock sustain revenue momentumCPI Data & Free Community Supported Trade Ideas - Newser
Why TuHURA Biosciences Inc. (PL3) stock benefits from AI revolutionMarket Performance Summary & Proven Capital Preservation Tips - Newser
Can TuHURA Biosciences Inc. (PL3) stock beat analyst consensusEarnings Overview Summary & Stock Portfolio Risk Management - Newser
Stock Market Recap: Can TuHURA Biosciences Inc. stock weather global recessionEntry Point & Fast Gain Stock Trading Tips - BỘ NỘI VỤ
Top investors say TuHURA Biosciences Inc (HURA) ticks everything they need - Setenews
TuHURA Biosciences shelf registration statement becomes effective By Investing.com - Investing.com Canada
TuHURA Biosciences’ Shelf Registration Statement Effective - TipRanks
TuHURA Biosciences shelf registration statement becomes effective - Investing.com
TuHURA Biosciences Announces Effective Shelf Registration Statement - TradingView
TuHURA Biosciences (NASDAQ:HURA) Downgraded to Sell Rating by Wall Street Zen - Defense World
Zacks Small Cap Issues Optimistic Forecast for HURA Earnings - Defense World
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of “Buy” from Brokerages - Defense World
How TuHURA Biosciences Inc. stock performs in weak economyJuly 2025 Momentum & Fast Entry High Yield Stock Tips - newser.com
Is TuHURA Biosciences Inc. stock safe for conservative investorsJuly 2025 Update & Short-Term Trading Opportunity Alerts - newser.com
Can TuHURA Biosciences Inc. (PL3) stock hit consensus price targets2025 Performance Recap & Technical Pattern Based Signals - newser.com
Why TuHURA Biosciences Inc. stock is trending among retail tradersJuly 2025 Outlook & Safe Capital Preservation Plans - newser.com
Is it too late to sell TuHURA Biosciences Inc.2025 Big Picture & Weekly High Return Opportunities - newser.com
What the charts say about TuHURA Biosciences Inc. today2025 Top Gainers & Technical Confirmation Trade Alerts - newser.com
TuHURA Biosciences releases updated pro forma financial statements following mergers - Investing.com Australia
TuHURA Biosciences Completes Acquisition of Kineta, Inc. - MSN
Will TuHURA Biosciences Inc. rebound enough to break evenPortfolio Update Summary & Free Fast Gain Swing Trade Alerts - newser.com
Will TuHURA Biosciences Inc. bounce back from current support2025 Price Momentum & Short-Term Trading Alerts - newser.com
What earnings revisions data tells us about TuHURA Biosciences Inc.Long Setup & Weekly Return Optimization Plans - newser.com
Tuhura Biosciences Inc Stock (HURA) Financials Data
There is no financial data for Tuhura Biosciences Inc (HURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):